Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics...
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is trading higher after receiving a green light from the...
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), which is developing a pipeline of targeted,...
Prescient Therapeutics: Mariam Mansour, PhD Mariam Mansour, PhD, Director of Clinical Development and Translational Sciences...
Prescient Therapeutics: Professor H. Miles Prince Professor H. Miles Prince AM, the Principal Investigator for...
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX,...
Prescient Therapeutics update report 2024 08 29
Clinical stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) had a cash and term deposit balance of $14.5...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has...
Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.